Recent Updates
Recently added Catalysts
ALT

Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcell, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

Wednesday, December 30, 2020 1 min read
Key Takeaway: Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcell, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

Full Press Release Details

Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcell, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B.
Tags: ALT Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Dec 30, 2020